Nuclear Medicine & Radiation Therapy

Trine Hjornevik

Publications

• Research Article
  Experiences from Introducing Standardized High Dose ¹³¹I-mIBG Treatment of Children with Refractory Neuroblastoma: Differences in Effective Dose to Patients and Exposure to Caregivers
  Author(s): Trine Hjornevik, Anne Catrine Martinsen, Signe Elise Hagve, Merethe Wigen Andersen, Ann Cecilie Mørk, Jan Gunnar Fjeld and Ellen RuudTrine Hjornevik, Anne Catrine Martinsen, Signe Elise Hagve, Merethe Wigen Andersen, Ann Cecilie Mørk, Jan Gunnar Fjeld and Ellen Ruud
  
  Aims: High dose 131I-meta iodobenzylguanidine (131I-mIBG) combined with radiosensitizing topotecan and peripheral blood stem cell support is a promising treatment regimen for children with neuroblastoma (NB). Here we present our first experiences, with particular focus on in vivo whole-body dosimetry and radiation exposure to family caregivers and hospital staff. Methods: Five children with relapsed or refractory NB were treated during 2012-2014. 131I-mIBG was administered in two fractions at two weeks apart, aiming for a total whole-body radiation-absorbed dose of 4 Gy. The 131I-mIBG activity for the 2nd administration was calculated on the basis of the measured whole-body dose following the 1st administration. Patients were isolated in a lead-shielded room, and all caregivers and staff received radiation safety training, and carried an electronic personal dosimeter. .. Read More»
  DOI: 10.4172/2155-9619.1000258

  Abstract PDF